

CAMZYOS[®] ▼ (mavacamten)

Healthcare Professional Checklist

▼ CAMZYOS is subject to additional monitoring to quickly identify new safety information. Healthcare professionals are asked to report any suspected adverse reactions.



Healthcare Professional Checklist

The checklist below includes information to consider when treating patients receiving CAMZYOS and counselling patients and/or their caregiver(s), more specifically in regard to the following risks:

- Embryo-foetal toxicity
- Heart failure due to systolic dysfunction
- Adverse events due to overexposure to mavacamten resulting from interaction with CYP2C19 inhibitors in ultrarapid and intermediate CYP2C19 metabolizers and moderate or strong CYP3A4 inhibitors in poor and normal CYP2C19 metabolizers

Please note that this checklist is not meant to be all-inclusive.

Prior to starting treatment
For patients of childbearing potential:
<input type="checkbox"/> Confirm a negative pregnancy test.
<input type="checkbox"/> Educate on the risk of embryo-foetal toxicity associated with CAMZYOS. Counsel on the need to avoid pregnancy and the need for an effective form of contraception during treatment with CAMZYOS and for 6 months following discontinuation.
<input type="checkbox"/> Instruct patients to contact you or another member of your healthcare team immediately if they become pregnant or suspect they may be pregnant.
For all patients:
<input type="checkbox"/> Complete an echocardiogram to confirm that the patient's LVEF is $\geq 55\%$ prior to initiating CAMZYOS.
<input type="checkbox"/> Patients should be genotyped for CYP2C19 phenotype in order to determine appropriate CAMZYOS dose.
<input type="checkbox"/> Assess for potential interactions involving CAMZYOS and any medicine (including prescription and over-the-counter medicines), herbal supplements and grapefruit juice. Detailed guidance on dose modifications/contraindications with concomitant medicines, based on the patient's CYP2C19 phenotype status, is included in the Summary of Product Characteristics (Table 1 and Table 2 of Section 4) .
<input type="checkbox"/> Inform the patient of the risk of heart failure associated with CAMZYOS and that they must consult their healthcare professional or seek medical attention immediately if they experience worsening, persistent or new shortness of breath, chest pain, fatigue, palpitations or leg swelling.
<input type="checkbox"/> Counsel the patient on the risks of potential interactions involving CAMZYOS and to not start or stop taking any medications or change the dose of any medication they are taking without talking to you first.
<input type="checkbox"/> Provide the patient with the Patient Guide and highlight the Patient Card within the guide.
During treatment at each clinical visit (as described in the Summary of Product Characteristics)
For patients of childbearing potential:
<input type="checkbox"/> Remind patients of the risk of embryo-foetal toxicity associated with CAMZYOS. Counsel on the need

Date of Health Authority Approval: [18March2024](#)

Local Approval Number: **3500-MT-2400001** – v1

to avoid pregnancy and the need for an effective form of contraception during treatment and for 6 months following discontinuation.
<input type="checkbox"/> Periodically check pregnancy status throughout treatment.
<input type="checkbox"/> Instruct patients to contact you or another member of your healthcare team immediately if they become pregnant or suspect they may be pregnant.
For all patients:
<input type="checkbox"/> Confirm LVEF is $\geq 50\%$ by echocardiogram assessment. If at any visit LVEF is $< 50\%$, interrupt treatment for 4 weeks and until LVEF returns to $\geq 50\%$.
<input type="checkbox"/> Assess the LVOT gradient with the Valsalva manoeuvre and adjust the dose per the guidance provided in the Summary of Product Characteristics Section 4.2 .
<input type="checkbox"/> Assess the patient for signs, symptoms and clinical findings of heart failure per the guidance provided in the Summary of Product Characteristics Sections 4.2 and 4.4 .
<input type="checkbox"/> Assess for intercurrent illnesses such as infections or arrhythmia (e.g., atrial fibrillation or other uncontrolled tachyarrhythmia).
<input type="checkbox"/> Assess for interactions involving CAMZYOS and any medicine (including prescription and over-the-counter medicines), herbal supplements and grapefruit juice that the patient has newly started, has changed the dose of or plans on taking in the future. Detailed guidance on dose modifications/contraindications with concomitant medicines, based on the patient's CYP2C19 phenotype status, is included in the Summary of Product Characteristics (Table 1 and Table 2 of Section 4) .
<input type="checkbox"/> Remind the patient of the risks associated with CAMZYOS and that they must consult their HCP or seek medical attention immediately if they experience worsening, persistent or new shortness of breath, chest pain, fatigue, palpitations or leg swelling.
<input type="checkbox"/> Counsel the patient on the risks of potential interactions involving CAMZYOS.
<input type="checkbox"/> Counsel the patient on actions to take in case of an overdose and missed or delayed doses.
<input type="checkbox"/> Provide the patient with the Patient Guide and Patient Card if needed.
After treatment
For patients of childbearing potential:
<input type="checkbox"/> Counsel patients on the need to avoid pregnancy and the need for an effective form of contraception for 6 months following discontinuation of CAMZYOS.

CYP=cytochrome P450; HCP=healthcare professional; LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract

Date of Health Authority Approval: 18March2024

Local Approval Number: 3500-MT-2400001– v1



REPORTING ADVERSE EVENTS

The safe use of CAMZYOS is of paramount importance. As part of our ongoing safety monitoring, Bristol Myers Squibb wishes to be informed of adverse events that have occurred during use of CAMZYOS. Please report any adverse events and pregnancies to: [AM Mangion Ltd on Tel No 00356 23976333 and email pv@ammangion.](mailto:pv@ammangion.com)

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form available online at <http://www.medicinesauthority.gov.mt/adrportal> and sent to the Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN or sent by email to: postlicensing.medicinesauthority@gov.mt



CONTACT DETAILS

If you have any questions regarding CAMZYOS or require more information, please contact Bristol Myers Squibb.

Telephone:	00 356 23976333
Email:	pv@ammangion.com